Takeda's polycythemia vera drug (in collaboration with Protagonist) has a third quarter PDUFA date.
“I think Takeda is a bit, I don't wanna say cagey about, exact PDUFA, but I think the guidance is a third quarter PDUFA.”
→ Read the source episode
Our resolution criterion
disputableFDA issues approval or rejection decision on Takeda/Protagonist's polycythemia vera drug in Q3 (July-September)
More from Biotech Hangout
Tarsus Pharmaceuticals' Alkias phase three Northstar study for gilderretinol will report data in H2 2029.
Ten X will meet with EMA to explore enriched patient populations for HFpEF drug following failed phase three.
Brian Skorney predicts Lilly's Lp(a) CVOT data may read out in 2029.
Daphne Zohar predicts Heidi Overton's FDA commissioner confirmation hearings will occur after the Senate summer recess.
Eric Schmidt predicts the HARMONY three study for evanesquimab will read out positively in 6-9 months.
Paul Matisse reports Biohaven's KV7 epilepsy drug is on partial clinical hold with phase 3 data coming soon.
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.